Psilocybin mushrooms assigned the status of “Advanced Therapy”
The US Food and Drug Administration (FDA) has granted psilocybin mushrooms the status of “Advanced Therapy” for the treatment of the major depressive disorder (MDP) and has initiated clinical trials.
Psilocybin Eliminates Symptoms of Depression and Anxiety Disorder
The results of opinion polls suggest that at least 16% of the population at least once in their life experienced symptoms of BDR. In the United States, this disease is considered the main cause of temporary disability for citizens aged 15 to 44 years. Most often, the disease occurs in residents of large cities, prone to stress and neuropsychic overload.
During preliminary studies, it was found that psilocybin helps fight the symptoms of depression and anxiety disorder, so the FDA allowed Usona Institute specialists to conduct clinical trials on the effects of the substance on the human psyche. The authors of the project are now recruiting volunteers with a diagnosis of BDR and are going to evaluate the effectiveness of a single dose of psychedelic to treat the disease. Director of the Institute Charles Ryson noted that mushrooms have high therapeutic potential and can be a good alternative to traditional antidepressants.
The effect of magic mushrooms lasts for six months
In April 2019, Australian doctors tested psilocybin in 30 terminally ill patients who developed an acute depressive disorder. Doctors found that a single dose of a substance changes a person’s view of life and helps him get rid of anxiety, while the action of a psychedelic lasts about six months.
A similar study was conducted in 2016 at Johns Hopkins American University, in which patients with cancer participated. Within six months after receiving psychedelics, 80% of patients were depressed about symptoms of depression and anxiety disorder, 83% of the subjects improved overall well-being, 66% of people included the experience of using psychedelics in the list of the five most important events in their life.
Johns Hopkins University employee Ronald Griffiths says the psilocybin test results exceeded expectations. Before the start of the tests, scientists doubted that psychedelic therapy would lead to positive results: “I thought that cancer patients would take psilocybin, see an existential void and return in even greater fear. However, they had the same changes in behavior and mood and healthy subjects. “
In October 2019, the University of Texas Health Center announced plans to launch psilocybin experiments in the treatment of resistant depression, a form of MDD that cannot be treated with antidepressants. Participants will take 25, 10 and 1 mg of the substance and complete the questionnaire one, three, six, nine and 12 weeks after use. Specialists are going to use the double-blind method to eliminate the likelihood of errors in determining the psychedelic effectiveness indicator.